Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2019-04-17 Regulatory Filings
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or fiscal period dates that would allow identification of a specific filing type. There is no indication of report titles, financial data, or announcements. Given the lack of discernible information, the document cannot be classified into any specific category and defaults to the fallback category for miscellaneous filings.
2019-04-17 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a detailed prospectus for an initial public offering (IPO) of common stock by Stoke Therapeutics, Inc. The text includes information about the offering, company overview, risk factors, use of proceeds, capitalization, management discussion and analysis, executive compensation, principal stockholders, and other typical sections of an IPO registration statement. Form S-1 is a registration document used by companies planning to go public and is not a financial report like an annual or quarterly report, nor is it an earnings release or a management discussion report. It is a regulatory filing related to capital raising and securities registration under the Securities Act of 1933. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including IPO registration statements.
2019-03-26 English
Regulatory Filings 2018
Regulatory Filings
2018-11-02 English
Regulatory Filings 2014
Regulatory Filings
2014-11-22 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.